The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder: Results From a European Multicenter Study
Open accessAbstract
OBJECTIVES: Very few studies have investigated clinical features associated with treatment-resistant depression (TRD) defined as failure of at least 2 consecutive antidepressant trials. The primary objective of this multicenter study was to identify specific clinical and demographic factors associated with TRD in a large sample of patients with major depressive episodes that failed to reach response or remission after at least 2 consecutive adequate antidepressant treatments. METHOD: A total of 702 patients with DSM-IV major depressive disorder, recruited from January 2000 to February 2004, were included in the analysis. Among them, 346 patients were considered as nonresistant. The remaining 356 patients were considered as resistant, with a 17-item Hamilton Rating Scale for Depression score remaining greater than or equal to 17 after 2 consecutive adequate antidepressant trials. Cox regression models were used to examine the association between individual clinical variables and TRD. RESULTS: Among the clinical features investigated, 11 variables were found to be associated with TRD. We found anxiety comorbidity (p < .001, odds ratio [OR] = 2.6), comorbid panic disorder (p < .001, OR = 3.2) and social phobia (p = .008, OR = 2.1), personality disorder (p = .049, OR = 1.7), suicidal risk (p = .001, OR = 2.2), severity (p = .001, OR = 1.7), melancholia (p = .018, OR = 1.5), a number of hospitalizations > 1 (p = .003, OR = 1.6), recurrent episodes (p = .009, OR = 1.5), early age at onset (p = .009, OR = 2.0), and nonresponse to the first antidepressant received lifetime (p = .019, OR = 1.6) to be the factors associated with TRD. CONCLUSIONS: Our findings provide a set of 11 relevant clinical variables associated with treatment resistance in major depressive disorder that can be explored at the clinical level. The statistical model used in this analysis allowed for a hierarchy of these variables (based on the OR) showing that comorbid anxiety disorder is the most powerful clinical factor associated with TRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This comorbidity pattern may also affect treatment outcomes, with pharmacotherapy studies indicating that comorbid SAD is associated with a poorer course of illness (Mulder, Joyce, Frampton, Luty, & Sullivan, 2006), treatment-resistant depression (Souery et al., 2007), and a greater number and earlier onset of depressive recurrences compared with patients without comorbid SAD (Holma, Holma, Melart”
From An Integrated, Acceptance-Based Behavioral Approach for Depression With Social Anxiety: Preliminary Results (2014) · cites this paper as Souery et al., 2007
In the citing paper
“Prevalence estimates of TRS, TRD, and treatment resistant OCD vary from 20-60% of the population with the condition. 26, 35–40”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [39]
In the citing paper
“Timing may add heterogeneous features: certain individuals may change readily with respect to certain symptoms, whereas other subjects may have opposite tendencies [41].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [41]
In the citing paper
“The basic flaw is to assume improvement to be a unitary phenomenon [41].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [41]
In the citing paper
“Comorbidities such as substance use disorder can undermine previously effective maintenance therapy [18]”
In the citing paper
“Approximately only one in two patients with major depressive disorder (MDD) respond to their antidepressant treatment ( Rush et al., 2006 , Souery et al., 2007 , Thomas et al., 2013 )”
From Self-blame-selective hyper-connectivity between anterior temporal and subgenual cortices predicts prognosis in major depressive disorder (2023) · cites this paper as Souery et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513
Self-citationSheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
Self-citationOstwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
(1997) · PubMed · Cited by 727
Perlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Treatment resistant depression: methodological overview and operational criteria
Souery, D., Amsterdam, J. D., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Racagni, G., Zohar, J., & Mendlewicz, J. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00004-2 · Cited by 443
Self-citation
Research works printed but not linked: 1
- a Copyright Daniel Souery, M.D. early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2004;55:875-881
Cited by
Sorted by citations
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Despite much investigation, consistent empirical associations between melancholic features and superior response to antidepressant medication have not been established (Dodd and Berk, 2004; Georgotas et al., 1986; Mallinckrodt et al., 2005; Nierenberg, 2003; Peselow et al., 1992; Souery et al., 2007; Trivedi et al., 2…”
BackgroundMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationA Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Defining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Self-citationTreatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Porcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331
Self-citationComorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment
Choi, K. W., Kim, Y., & Jeon, H. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9705-0_14 · Cited by 339
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Self-citationIsingrini, E., Camus, V., Le Guisquet, A.-M., Pingaud, M., Devers, S., & Belzung, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010404 · Cited by 277
Dong, M., Zeng, L.-N., Lu, L., Li, X.-H., Ungvari, G. S., Ng, C. H., Chow, I. H. I., Zhang, L., Zhou, Y., & Xiang, Y.-T. (2019) · Psychological Medicine · doi:10.1017/s0033291718002301 · Cited by 263
The severity of psychiatric disorders
Zimmerman, M., Morgan, T. A., & Stanton, K. (2018) · World Psychiatry · doi:10.1002/wps.20569 · Cited by 227
Carlo, V. D., Calati, R., & Serretti, A. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.034 · Cited by 219
Self-citationStaging methods for treatment resistant depression. A systematic review
Ruhé, H. G., van Rooijen, G., Spijker, J., Peeters, F. P. M. L., & Schene, A. H. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.02.020 · Cited by 210
Cai, H. X., Xie, X.-M., Zhang, Q., Cui, X., Lin, J.-X., Sim, K., Ungvari, G. S., Zhang, L., & Xiang, Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.690130 · Cited by 258
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
Impact of pain on the course of depressive and anxiety disorders
Gerrits, M. M. J. G., Vogelzangs, N., van Oppen, P., van Marwijk, H. W. J., van der Horst, H., & Penninx, B. W. J. H. (2012) · Pain · doi:10.1016/j.pain.2011.11.001 · Cited by 199
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
Hennings, J. M., Owashi, T., Binder, E. B., Horstmann, S., Menke, A., Kloiber, S. M., Dose, T., Wollweber, B., Spieler, D., Messer, T., et al. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.002 · Cited by 197
Eisendrath, S. J., Gillung, E., Delucchi, K. L., Segal, Z. V., Nelson, J. C., McInnes, L. A., Mathalon, D. H., & Feldman, M. D. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442260 · Cited by 187
Pizzagalli, D. A., Webb, C. A., Dillon, D. G., Tenke, C. E., Kayser, J., Goer, F., Fava, M., McGrath, P., Weissman, M., Parsey, R., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0252 · Cited by 189
El-Khalili, N., Joyce, M. A., Atkinson, S. D., Buynak, R. J., Datto, C. J., Lindgren, P., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000015 · Cited by 188
Gender differences in antidepressant drug response
Keers, R., & Aitchison, K. J. (2010) · International Review of Psychiatry · doi:10.3109/09540261.2010.496448 · Cited by 187
Prevalence of treatment-resistant depression in primary care: cross-sectional data
Thomas, L., Kessler, D., Campbell, J., Morrison, J., Peters, T. J., Williams, C., Lewis, G., & Wiles, N. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x675430 · Cited by 175
Identifying fast-onset antidepressants using rodent models
Ramaker, M. J., & Dulawa, S. C. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.36 · Cited by 183
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179
Kemp, A. H., Gordon, E., Rush, A. J., & Williams, L. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900017120 · Cited by 170
Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study
Webb, C. A., Trivedi, M. H., Cohen, Z. D., Dillon, D. G., Fournier, J. C. J., Goer, F., D, M. F. M., McGrath, P. J., Weissman, M. M., Parsey, R. V., et al. (2018) · Psychological Medicine · doi:10.1017/s0033291718001708 · Cited by 177
Reynolds, C. F., Butters, M. A., Lopez, O., Pollock, B. G., Dew, M. A., Mulsant, B. H., Lenze, E. J., Holm, M., Rogers, J. C., Mazumdar, S., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.184 · Cited by 171
Effectiveness of psychoeducation for depression: A systematic review
Tursi, M. F. D. S., Baes, C. V. W., Camacho, F. R. D. B., Tofoli, S. M. D. C., & Juruena, M. F. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413491154 · Cited by 173
Lundberg, J., Cars, T., Lööv, S., Söderling, J. K., Sundström, J., Tiihonen, J., Levál, A., Gannedahl, A., Björkholm, C., Själin, M., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3860 · Cited by 168
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
Self-citationFrank, E., Cassano, G., Rucci, P., Thompson, W. K., KRAEMER, H. C., Fagiolini, A. M., Maggi, L., Kupfer, D. J., Shear, M. K., Houck, P. R., et al. (2010) · Psychological Medicine · doi:10.1017/s0033291710000553 · Cited by 151
Kautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Fabbri, C., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12959 · Cited by 148
Self-citationTreatment-Resistant Depression in Primary Care across Canada
Rizvi, S. J., Grima, E., Tan, M., Rotzinger, S., Lin, P., McIntyre, R. S., & Kennedy, S. H. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900702 · Cited by 144
Mendlewicz, J. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970802503086 · Cited by 143
Self-citationTreatment-resistant depression: are animal models of depression fit for purpose?
Willner, P., & Belzung, C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4034-7 · Cited by 153
Risk factors for treatment resistance in unipolar depression: A systematic review
Bennabi, D., Aouizerate, B., El‐Hage, W., Doumy, O., Molière, F., Courtet, P., Nieto, I., Bellivier, F., Bubrovsky, M., Vaïva, G., et al. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.020 · Cited by 149
Schosser, A., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., & Kasper, S. F. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.02.006 · Cited by 136
Self-citationDold, M., Bartova, L., Souery, D., Mendlewicz, J., Serretti, A., Porcelli, S., Zohar, J., Montgomery, S., & Kasper, S. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.020 · Cited by 131
Self-citationBareš, M., Brunovský, M., Kopeček, M., Novák, T., Stopková, P., Kožený, J., Šóš, P., Krajča, V., & Höschl, C. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.03.001 · Cited by 132
Craighead, W. E., & Dunlop, B. W. (2011) · Annual Review of Psychology · doi:10.1146/annurev.psych.121208.131653 · Cited by 130
Wiles, N., Thomas, L., Abel, A., Barnes, M., Carroll, F., Ridgway, N., Sherlock, S., Turner, N., Button, K., Odondi, L., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18310 · Cited by 127
Evidence-based pharmacotherapy of treatment-resistant unipolar depression
Dold, M., & Kasper, S. F. (2016) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1248852 · Cited by 126
Self-citationSouery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Bollen, J., Demyttenaere, K., Kasper, S. F., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182228619 · Cited by 118
Self-citationLymphoblastoid Cell Lines in Pharmacogenomic Discovery and Clinical Translation
Wheeler, H. E., & Dolan, M. E. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.121 · Cited by 118
Mechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111
A transdiagnostic network for psychiatric illness derived from atrophy and lesions
Taylor, J. J., Lin, C., Talmasov, D., Ferguson, M. A., Schaper, F. L. W. V. J., Jiang, J., Goodkind, M. S., Grafman, J. H., Etkin, A., Siddiqi, S., et al. (2023) · Nature Human Behaviour · doi:10.1038/s41562-022-01501-9 · Cited by 114
Sackeim, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., Demitrack, M. A., George, M. S., Prudic, J., Thase, M. E., & Rush, A. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.021 · Cited by 109
The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review
Demyttenaere, K., & Van Duppen, Z. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy052 · Cited by 98
Self-citationNovel drug developmental strategies for treatment‐resistant depression
Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15753 · Cited by 116
Major depression: the importance of clinical characteristics and treatment response to prognosis
Katon, W. J., Unützer, J., & Russo, J. E. (2009) · Depression and Anxiety · doi:10.1002/da.20613 · Cited by 114
Paolucci, S., Iosa, M., Coiro, P., Venturiero, V., Savo, A., Angelis, D. D., & Morone, G. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00926 · Cited by 111
Tadić, A., Wagner, S., Höch, J., Başkaya, Ö., von Cube, R., Skaletz, C., Lieb, K., & Dahmen, N. (2009) · Psychopathology · doi:10.1159/000224149 · Cited by 110
Balestri, M., Calati, R., Souery, D., Kautzky, A., Kasper, S. F., Montgomery, S., Zohar, J., Mendlewicz, J., & Serretti, A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.033 · Cited by 105
Self-citationTherapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 101
Bennabi, D., Charpeaud, T., Yrondi, A., Genty, J., Destouches, S., Lancrenon, S., Allaïli, N., Bellivier, F., Bougerol, T., Camus, V., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2237-x · Cited by 114
Lai, C., Hsu, Y.-Y., & Wu, Y. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.002 · Cited by 100
Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression
Vittengl, J. R., Jarrett, R. B., Weitz, E., Hollon, S. D., Twisk, J., Cristea, I., David, D., DeRubeis, R. J., Dimidjian, S., Dunlop, B. W., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040492 · Cited by 97
Fleck, M. P. D. A., Berlim, M. T., Lafer, B., Sougey, É. B., Porto, J. A. D., Brasil, M. A. A., Juruena, M. F., & Hetem, L. A. (2009) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462009000500003 · Cited by 101
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
Iovieno, N., van Nieuwenhuizen, A., Clain, A., Baer, L., & Nierenberg, A. A. (2011) · Depression and Anxiety · doi:10.1002/da.20768 · Cited by 98
Neurogenesis and antidepressant action
Park, S. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03043-5 · Cited by 101
Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden
Reutfors, J., Andersson, T. M.-L., Brenner, P., Brandt, L., DiBernardo, A., Li, G., Hägg, D., Wingård, L., & Bodén, R. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.030 · Cited by 94
Bareš, M., Brunovský, M., Novák, T., Kopeček, M., Stopková, P., Šóš, P., Krajča, V., & Höschl, C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.03.007 · Cited by 94
Zhang, C., Li, Z., Wu, Z., Chen, J., Wang, Z., Peng, D., Hong, W., Yuan, C., Wang, Z., Yu, S., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3297-0 · Cited by 95
Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
Kautzky, A., Baldinger, P., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Serretti, A., Lanzenberger, R. R., & Kasper, S. F. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.001 · Cited by 92
Self-citationPersistence and remission of ADHD during adulthood: a 7-year clinical follow-up study
Karam, R. G., Breda, V., Picon, F. A., Rovaris, D. L., Victor, M. M., Salgado, C. A. I., Vitola, E. S., Silva, K. L., Guimarães-da-Silva, P. O., Mota, N. R., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291714003183 · Cited by 113
Effects of illness duration and treatment resistance on grey matter abnormalities in majordepression
Serra-Blasco, M., Portella, M. J., Gómez-Ansón, B., de Diego-Adeliño, J., Vives-Gilabert, Y., Puigdemont, D., Granell, E., Santos, A., Álvarez, E., & Pérez, V. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.116228 · Cited by 87
The impact of Ayahuasca on suicidality: results from a randomized controlled trial
Zeifman, R. J., Palhano-Fontes, F., Hallak, J., Arcoverde, E., Maia-Oliveira, J. P., & Araujo, D. B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01325 · Cited by 87
Kasper, S. F., Cubała, W. J., Fagiolini, A. M., Ramos‐Quiroga, J. A., Souery, D., & Young, A. H. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1836399 · Cited by 89
Self-citationNeurobehavioral Abnormalities in First-Degree Relatives of Individuals With Autism
Mosconi, M. W., Kay, M., D’Cruz, A.-M., Guter, S., Kapur, K., Macmillan, C., Stanford, L. D., & Sweeney, J. A. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.87 · Cited by 84
Finding factors that predict treatment-resistant depression: results of a cohort study
Cepeda, M. S., Reps, J., & Ryan, P. (2018) · Depression and Anxiety · doi:10.1002/da.22774 · Cited by 80
Risk factors of treatment resistance in major depression: Association with bipolarity
Dudek, D., RYBAKOWSKI, J. K., Siwek, M., Pawłowski, T., Łojko, D., Roczeń, R., & Kiejna, A. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.03.001 · Cited by 82
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
Kim, N., Huh, H.-J., & Chae, J. (2015) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2015.04.009 · Cited by 83
Woo, Y., Seo, H.-J., McIntyre, R., & Bahk, W.-M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010080 · Cited by 79
Schmidt, F. M., Schindler, S., Adamidis, M., Strauß, M., Tränkner, A., Trampel, R., Walter, M., Hegerl, U., Turner, R., Geyer, S., et al. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0675-8 · Cited by 76
Epigenetics: A missing link between early life stress and depression
Juruena, M. F., Gadelrab, R., Cleare, A. J., & Young, A. H. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110231 · Cited by 80
Early life stress, HPA axis, and depression.
Tofoli, S. M. D. C., Baes, C. V. W., Martins, C. M. S., & Juruena, M. F. (2011) · Psychology & Neuroscience · doi:10.3922/j.psns.2011.2.008 · Cited by 73
Neuropsychological changes in melancholic and atypical depression: A systematic review
Bosaipo, N. B., Foss, M. P., Young, A. H., & Juruena, M. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.014 · Cited by 79
Lai, C., & Hsu, Y. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000829 · Cited by 75
Zheng, H., Zhang, L., Li, L., Liu, P., Gao, J., Liu, X., Zou, J., Zhang, Y., Liu, J., Zhang, Z., et al. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.009 · Cited by 75
Kocabas, N. A., Antonijevic, I., Faghel, C., Forray, C., Kasper, S., Lecrubier, Y., Linotte, S., Massat, I., Mendlewicz, J., Noro, M., et al. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833d18f8 · Cited by 74
Self-citationThe hidden third: improving outcome in treatment-resistant depression
Schlaepfer, T. E., Ågren, H., Monteleone, P., Gastó, C., Pitchot, W., Rouillon, F., Nutt, D., & Kasper, S. F. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431748 · Cited by 76
Self-citationSerretti, A., Calati, R., Massat, I., Linotte, S., Kasper, S. F., Lecrubier, Y., Espel, R. S., Bollen, J., Zohar, J., Berlo, J. A., et al. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832e5b0d · Cited by 74
Self-citationCaraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S. F., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 76
Self-citationFugger, G., Dold, M., Bartova, L., Kautzky, A., Souery, D., Mendlewicz, J., Serretti, A., Zohar, J., Montgomery, S., Frey, R., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.03.011 · Cited by 69
Self-citationTanti, A., & Belzung, C. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1612-z · Cited by 75
Bakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W. M., Liebowitz, M., & Khan, A. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130040 · Cited by 70
Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer
Prabhavalkar, K. S., Poovanpallil, N. B., & Bhatt, L. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00242 · Cited by 74
A Genome-wide Association Meta-analysis of Preschool Internalizing Problems
Benke, K. S., Nivard, M. G., Velders, F. P., Walters, R. K., Pappa, I., Scheet, P. A., Xiao, X., Ehli, E. A., Palmer, L. J., Whitehouse, A., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.12.028 · Cited by 63
Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D
Clark, S. L., Adkins, D. E., Åberg, K. A., Hettema, J. M., McClay, J. L., de Souza, R. P., & van den Oord, E. J. C. G. (2011) · Psychological Medicine · doi:10.1017/s003329171100239x · Cited by 67
A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression
Murphy, J., Sarris, J. J., & Byrne, G. J. (2017) · Depression Research and Treatment · doi:10.1155/2017/4176825 · Cited by 77
Dold, M., Kautzky, A., Bartova, L., Rabl, U., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.005 · Cited by 66
Self-citationElectroconvulsive therapy in treatment resistant depression
Subramanian, S., Lopez, R., Zorumski, C. F., & Cristancho, P. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120095 · Cited by 75
The Gene Encoding Protocadherin 9 (PCDH9), a Novel Risk Factor for Major Depressive Disorder
Xiao, X., Zheng, F., Chang, H., Ma, Y., Yao, Y., Luo, X., & Li, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.241 · Cited by 65
Metadata
- Authors
- Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., Mendlewicz, J., & Group for the Study of Resistant Depression (GSRD)
- Affiliations
- Université Libre de Bruxelles (BE)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-07-15
- Volume
- 68
- Issue
- 07
- Pages
- 1062-1070
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1969010498
- Cited by
- 521
- References
- 22
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 26 · 2023: 30 · 2022: 26 · 2021: 54 · 2020: 35 · 2019: 46 · 2018: 31 · 2017: 22 · 2016: 23 · 2015: 25 · 2014: 27 · 2013: 29 · 2012: 21
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Les Laboratories Pierre Fabre
- Fonds De La Recherche Scientifique - FNRS
- Servier
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, major depressive disorder, antidepressant non-response, anxiety comorbidity, panic disorder, social anxiety disorder, personality disorders, suicide risk, melancholia, depression severity, hospitalization, recurrent depression, age of onset, risk factors
- MeSH terms
- Adult, Aged, Antidepressive Agents, Mental Disorders, Major Depressive Disorder, Drug Resistance, Europe, Female, Follow-Up Studies, Hospitalization, Humans, Male, Middle Aged, Recurrence, Comorbidity, Treatment Failure, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
